<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05044156</url>
  </required_header>
  <id_info>
    <org_study_id>Usak State Hospital</org_study_id>
    <nct_id>NCT05044156</nct_id>
  </id_info>
  <brief_title>Investigation of the Relationship Between Salivary Histatine-5 Level and Vaginal Candidiasis in Women</brief_title>
  <official_title>Investigation of the Relationship Between Salivary Histatine-5 Level and Vaginal Candidiasis in Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Usak State Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Usak State Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The low Histatine-5 (HST-5) level of the saliva can lead to vaginal candidiasis. Because&#xD;
      HST-5 level in the saliva can effect vaginal Ph, flora and local defence mechanisms.&#xD;
&#xD;
      Histatine-5 is secreted in the parotis and submandibular glands. İt riches histidine amino&#xD;
      ascid and have antifungal activity. Salivary proteins and their plasma levels were found as&#xD;
      similar in the literature.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Women with regularly menstrual cycle will enroll in the study than will separate two groups:&#xD;
&#xD;
      Study group: women with vaginal candidiasis ( diagnosed by clinic and lab.)&#xD;
&#xD;
      Control group: women ( not have any vaginal infections candida and others)&#xD;
&#xD;
      Saliva samples will be taken from two groups than HST-5 level will be analyzed. Finally HST-5&#xD;
      levels of the two groups will be compared .&#xD;
&#xD;
      Women with diabetes, immun deficiency, pregnancy, virgin, menopausal period , premature&#xD;
      ovarian failure will be excluded.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Anticipated">September 2021</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">October 2021</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>3 Months</target_duration>
  <primary_outcome>
    <measure>SALIVARY HISTATINE-5 LEVEL IN THE WOMEN WITH VAGINAL CANDIDIASIS</measure>
    <time_frame>1 month</time_frame>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Vaginal Infection</condition>
  <condition>Candidiasis</condition>
  <arm_group>
    <arm_group_label>Case group</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>salivary sample</intervention_name>
    <description>salivary sample</description>
    <arm_group_label>Case group</arm_group_label>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        women with regularly menstrual cycle, diagnosed candidal vaginosis and not have any vaginal&#xD;
        infection.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria: women with regularly menstrual cycle , diagnosed candidal vaginosis and&#xD;
        not have any vaginal infection.&#xD;
&#xD;
        -&#xD;
&#xD;
        Exclusion Criteria: diabetes, immun deficiency, menopause, premature ovarian failure,&#xD;
        pregnancy, virgin&#xD;
&#xD;
        -&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Female</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>İrem Şenyuva</name>
      <address>
        <city>Usak</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <reference>
    <citation>Khurshid Z, Najeeb S, Mali M, Moin SF, Raza SQ, Zohaib S, Sefat F, Zafar MS. Histatin peptides: Pharmacological functions and their applications in dentistry. Saudi Pharm J. 2017 Jan;25(1):25-31. doi: 10.1016/j.jsps.2016.04.027. Epub 2016 May 4. Review.</citation>
    <PMID>28223859</PMID>
  </reference>
  <reference>
    <citation>Loo JA, Yan W, Ramachandran P, Wong DT. Comparative human salivary and plasma proteomes. J Dent Res. 2010 Oct;89(10):1016-23. doi: 10.1177/0022034510380414. Epub 2010 Aug 25. Review.</citation>
    <PMID>20739693</PMID>
  </reference>
  <reference>
    <citation>Liao H, Liu S, Wang H, Su H, Liu Z. Efficacy of Histatin5 in a murine model of vulvovaginal candidiasis caused by Candida albicans. Pathog Dis. 2017 Aug 31;75(6). doi: 10.1093/femspd/ftx072.</citation>
    <PMID>28645176</PMID>
  </reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 4, 2021</study_first_submitted>
  <study_first_submitted_qc>September 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 14, 2021</study_first_posted>
  <last_update_submitted>September 14, 2021</last_update_submitted>
  <last_update_submitted_qc>September 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Usak State Hospital</investigator_affiliation>
    <investigator_full_name>Irem Senyuva</investigator_full_name>
    <investigator_title>M.D, Obstetrics and Gynecology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Candidiasis</mesh_term>
    <mesh_term>Candidiasis, Vulvovaginal</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

